The potential of biomarkers of fibrosis in chronic lung allograft dysfunction

Eline A van der Ploeg; Barbro N Melgert; Janette K Burgess; C Tji Gan

doi:10.1016/j.trre.2021.100626

The potential of biomarkers of fibrosis in chronic lung allograft dysfunction

Transplant Rev (Orlando). 2021 Jul;35(3):100626. doi: 10.1016/j.trre.2021.100626. Epub 2021 May 4.

Authors

Eline A van der Ploeg¹, Barbro N Melgert², Janette K Burgess³, C Tji Gan⁴

Affiliations

¹ University of Groningen, University Medical Centre Groningen, Department of Pulmonary Medicine, PO Box 30. 001, 9700, RB, Groningen, the Netherlands. Electronic address: e.a.b.van.der.ploeg@umcg.nl.
² University of Groningen, Department of Molecular Pharmacology, Groningen Research Institute of Pharmacy, PO box 196, 9700, AD, Groningen, the Netherlands; University of Groningen, University Medical Centre Groningen, Groningen Research Institute for Asthma and COPD (GRIAC), University Medical Center Groningen, PO Box 30.001, 9700, RB, Groningen, the Netherlands. Electronic address: b.n.melgert@rug.nl.
³ University of Groningen, University Medical Centre Groningen, Groningen Research Institute for Asthma and COPD (GRIAC), University Medical Center Groningen, PO Box 30.001, 9700, RB, Groningen, the Netherlands; University of Groningen, University Medical Centre Groningen, Department of Pathology and Medical Biology, PO Box 30.001, 9700, RB, Groningen, the Netherlands. Electronic address: j.k.burgess@umcg.nl.
⁴ University of Groningen, University Medical Centre Groningen, Department of Pulmonary Medicine, PO Box 30. 001, 9700, RB, Groningen, the Netherlands. Electronic address: c.t.gan@umcg.nl.

PMID: 33992914
DOI: 10.1016/j.trre.2021.100626

Abstract

Chronic lung allograft dysfunction (CLAD) is the major long-term cause of morbidity and mortality after lung transplantation. Both bronchiolitis obliterans syndrome and restrictive lung allograft syndrome, two main types of CLAD, lead to fibrosis in either the small airways or alveoli and pleura. Pathological pathways in CLAD and other types of fibrosis, for example idiopathic pulmonary fibrosis, are assumed to overlap and therefore fibrosis biomarkers could aid in the early detection of CLAD. These biomarkers could help to differentiate between different phenotypes of CLAD and could, in comparison to biomarkers of inflammation, possibly distinguish an infectious event from CLAD when a decline in lung function is present. This review gives an overview of known CLAD specific biomarkers, describes new promising fibrosis biomarkers currently investigated in other types of fibrosis, and discusses the possible use of these fibrosis biomarkers for CLAD.

Keywords: BOS; Biomarker; CLAD; Fibrosis; Lung transplantation; RAS.

Publication types

Review

MeSH terms

Allografts
Biomarkers
Bronchiolitis Obliterans* / diagnosis
Bronchiolitis Obliterans* / etiology
Fibrosis
Humans
Lung
Lung Transplantation* / adverse effects

Substances

Biomarkers